Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach

Journal of Chemotherapy

Volumn 16, Issue SUPPL. 4, 2004, Pages 25-30

  Peters, G J ^a   Smorenburg, C H ^a   Van Groeningen, C J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dihydropyrimidine dehydrgenase; Oral 5FU dormulations; S 1; Tailored therapy; Thymidylate synthase; UFT

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG METABOLIZING ENZYME; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MESSENGER RNA; NEW DRUG; OXALIPLATIN; TEGAFUR; THYMIDYLATE SYNTHASE; UFT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DRUG ACTIVATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; DRUG RESISTANCE; DRUG RESPONSE; ENZYME ACTIVITY; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; HUMAN; METHODOLOGY; PATIENT SELECTION; PHARMACOGENETICS; PHARMACOGENOMICS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TAILORED THERAPY;

EID: 11244258378     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2004.16.supplement-1.25     Document Type: Conference Paper

References (46)

1. Peters GJ, Schornagel J, Milano GA. Clinical pharmacokinetics of antimetabolites. Cancer Surv 1993; 17: 123-156.
2. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004; 40: 939-950.
3. Gamelin E, Boisdron-Celle M, Delva R, Regimbeau C, Cailleux PE, Alleaume C, et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 1998; 16: 1470-1478.
4. Lu Z, Zhang R, Diasio RB. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin Pharmacol Ther 1995; 58: 512-522.
5. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6, 1322-1327.
6. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004; 22: 529-536.
7. Spears CP, Gustavsson BG, Berne M, Frosing R, Berstein L, Hays AA. Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Cancer Res 1988; 48: 5894-5900.
8. Van Triest B, Peters GJ. Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer. Oncology 1999; 57: 179-194
9. Peters GJ, Van der Wilt CL, Van Groeningen CJ, Meijer S, Smid K, Pinedo HM. Thymidylate synthase inhibition after administration of 5-fluorouracil with or without leucovorin; implications for treatment with 5-fluorouracil. J Clin Oncol 1994; 12: 2035-2042.
10. Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7: 890-899.
11. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994; 12: 2640-2647.
12. Backus HHJ, Van Riel JMGH, Van Groeningen CJ, Vos W, Dukers DF, Bloemena E, et al. Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Ann. Oncol 2001; 12: 779-785.
13. Horikoshi T, Danenberg KD, Stadlbauer TH, Volkenandt M, Shea LC, Aigner K, et al. Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res 1992; 52: 108-16.
14. Van Triest B, Loftus BM, Pinedo HM, Backus HH, Schoenmakers P, Telleman F, et al. Thymidylate synthase expression in patients with colorectal carcinoma using a polyclonal thymidylate synthase antibody in comparison to the TS 106 monoclonal antibody. J. Histochem Cytochem 2000; 48: 755-760.
15. Findlay MP, Cunningham D, Morgan G, Clinton S, Hardcastle A, Aherne GW. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 1997; 75: 903-909.
16. Barrat PL, Seymour MT, Stenning SP, GeorgiadesI, Walker C, Birbeck K, et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with coon cancer: a molecular study. Lancet 2002; 360: 1381-1391.
17. Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 2001; 61: 5193-5201.
18. Van Triest B, Pinedo HM, Giaccone G, Peters GJ. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol 2000; 11: 385-391
19. Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, Kim G, et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003; 21: 241-250.
20. Wang TL, Diaz LA Jr, Romans K, Bardelli A, Saha S, Galizia G, et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci USA 2004; 101: 3089-3094.
21. Mauritz R, Beumer IJ, Marsh S, McLeod HL, Smid K, Van Groeningen CJ, et al. Polymorphism of the thymidylate synthase gene and thymidylate synthase levels in colon cancer cell lines and different tissues of colorectal cancer patients. Nucleosides, Nucleotides & Nucleic Acids 2004, in press
22. Marsh S, McKay JA, Cassidy J, McLeod HL. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 2001; 19: 383-386.
23. Iacopetta B, Grieu F, Joseph D, Elsaleh H. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001; 85: 827-831.
24. Villafranca E, Okruzhnov Y, Dominguez MA, Garcia-Foncillas J, Azinovic I, Martinez E, et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001; 19, 1779-1786.
25. Kawakami K, Watanabe G. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 2003; 63: 6004-6007
26. Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer-a tale of two drugs: implications for biochemical modulation. J Clin Oncol 1997; 15: 368-381.
27. Van Laar JAM, Van der Wilt CL, Smid K, Noordhuis P, Rustum YM, Pinedo HM, Peters GJ. Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine Colon 26-b carcinoma tumor model. Clin Cancer Res 1996; 2: 1327-1333.
28. Peters GJ, Backus HHJ, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002; 1587: 194-205.
29. Codacci-Pisanelli G, Van der Wilt CL, Smid K, Noordhuis P, Voorn D, Pinedo HM, Peters GJ. High-dose 5-fluorouracil with uridine-diphosphoglucose rescue increases thymidylate synthase inhibition but not 5-fluorouracil incorporation into RNA in murine tumors. Oncology 2002; 62: 363-370.
30. Noordhuis P, Holwerda U, Van Der Wilt CL, Van Groeningen CJ, Smid K, Meijer S, et al. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol 2004; 15: 1025-1032.
31. Aschele C, Debernardis D, Bandelloni R, Cascinu S, Catalano V, Giordani P, et al. Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. Ann Oncol 2002; 13: 1882-1892.
32. Van Triest B, Pinedo HM, Blaauwgeers JL, van Diest PJ, Schoenmakers PS, Voorn DA, et al. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res, 2000; 6, 1063-1072.
33. De Bruin M, Smid K, Laan AC, Noordhuis P, Fukushima M, Hoekman K, et al. Rapid disappearance of deoxyribose-1-phosphate in platelet derived endothelial cell growth factor/thymidine phosphorylase overexpressing cells. Biochem Biophys Res Comm 2003; 301: 675-679.
34. Peters GJ. Relative role of 5-fluorouracil activation and inactivation pathways in its cytotoxic effects; Preclinical and clinical modulation. Chapter 1 from: Anticancer Drug Development Guide: Fluoropyrimidines in Cancer Therapy (Ed. Y.M. Rustum), Humana Press Inc., Totowa, NJ; 2002: 1-27.
35. Komatsu T, Yamazaki H, Shimada N, Nakajima M, Yokoi T. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos 2000; 28: 1457-1463.
36. Peters GJ, Noordhuis P, Van Groeningen CJ, Giaccone G, Holwerda U, Voorn D, et al. The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. Clin Cancer Res 2004; 10: 4072-4076.
37. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-491.
38. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, Traxler P. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 2004; 64: 2333-2337.
39. Mini E, Trave F, Rustum YM, Bertino JR. Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. Pharmacol Ther 1990; 47: 1-19.
40. Peters GJ, Van Groeningen CJ. Clinical relevance of biochemical modulation of 5-fluorouracil. Ann Oncol 1991; 2: 469-480.
41. Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994; 12: 960-969.
42. Mauritz R, Schwabe W, Noordhuis P, Smid K, McLeod HL, Behnke D, et al. Comparison of mRNA expression levels determined with Taq-man and competitive template RT-PCR. Nucleosides, Nucleotides & Nucleic Acids, 2004; in press
43. Smorenburg C, Peters GJ, Van Groeningen CJ, Noordhuis P, Dercksen W, Loves W, et al. First line tailored chemotherapy in advanced colorectal cancer (ACRC) with 5-fluorouracil/leucovorin (5FU/LV) or oxaliplatin/irinotecan chosen by the expression of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase. Proc ASCO Annual Meeting 2004: Abstract 3624.
44. Becouarn Y, Gamelin E, Coudert B, Negrier S, Pierga JY, Raoul JL, et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. J Clin Oncol 2001; 19: 4195-4201.
45. Wasserman E, Sutherland W, Cvitkovic E. Irinotecan plus oxaliplatin: a promising combination for advanced colorectal cancer. Clin Colorectal Cancer 2001; 1: 149-53.
46. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.